NL-OMON34665
Withdrawn
Not Applicable
Application of mesenchymal stem cells in patients with end-stage renal disease - MiSOT-2
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 16
- Status
- Withdrawn
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Kidney transplantation candidate with a willing donor
- •Pre\-emptive (not yet on dialysis)
- •Glomerular filtration rate is between 15 and 25
- •Female subjects must be non\-pregnant and non\-breast\-feeding
Exclusion Criteria
- •Subject is HIV1, HIV2, Hepatitis B, Hepatitis C or HTLV positive
- •Subject has active infection or abscess
- •Subject has evidence or prior history of active malignancy
- •Subject previously received an organ transplant
- •Subject uses immunosuppressive medication
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Clinical research using the mesenchymal stem cells from autologous fat tissue of Alzheimer dementiaJPRN-jRCTb050190035OOYAMA TAKAYUKI3
Recruiting
Phase 1
Cell therapy with use of mesenchymal stem cells in infertile women with Thin EndometriumIRCT20230222057500N1Tehran University of Medical Sciences10
Completed
Not Applicable
Efficacy of mesenchymal stem cells for treatment of refractory acute GVHD after stem cell transplantatiorefractoty acute GVHD after stem cell transplantationJPRN-C000000423Jichi Medical University, Department of Medicine, Division of Hematology5
Active, not recruiting
Not Applicable
Application of Mesenchymal Stem Cells and full of plasma in the management of the burn wound in patients with large burn injury - Stem CellsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2012-001596-36-ESMIGUEL CASARES FERNÁNDEZ-ALVÉS
Active, not recruiting
Not Applicable
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04]EUCTR2012-002553-38-ESItziar Astigarraga Aguirre